Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Adzenys ER

&times

Overview

What is Adzenys ER?

ADZENYS ER (amphetamine) extended-release oral suspension contains a 3 to 1 ratio of - to -amphetamine, a central nervous system stimulant.

The labeled strength reflects the amount of amphetamine in ADZENYS ER whereas the strengths of the mixed salts of a single-entity amphetamine products are in terms of the amount of amphetamine salts. Table 1 in Section 2.5 details the equivalent amounts of active ingredient in these products.



What does Adzenys ER look like?



What are the available doses of Adzenys ER?

Extended-release oral suspension containing 1.25 mg amphetamine per mL. ()

What should I talk to my health care provider before I take Adzenys ER?

How should I use Adzenys ER?

ADZENYS ER is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older .

Prior to treating patients with ADZENYS ER, assess for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) .

Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy. Maintain careful prescription records, educate patients about abuse, monitor for signs of abuse and overdose, and periodically re-evaluate the need for ADZENYS ER use .


What interacts with Adzenys ER?

Sorry No Records found


What are the warnings of Adzenys ER?

Sorry No Records found


What are the precautions of Adzenys ER?

Sorry No Records found


What are the side effects of Adzenys ER?

Sorry No records found


What should I look out for while using Adzenys ER?

ADZENYS ER is contraindicated:

CNS stimulants, including ADZENYS ER, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy

,

]


What might happen if I take too much Adzenys ER?

Consult with a Certified Poison Control Center (1-800-222-1222) for up-to-date guidance and advice for treatment of overdosage. Individual patient response to amphetamines varies widely. Toxic symptoms may occur idiosyncratically at low doses.

Manifestations of amphetamine overdose include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression usually follow the central nervous system stimulation. Other reactions include arrhythmias, hypertension or hypotension, circulatory collapse, nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.


How should I store and handle Adzenys ER?

Storage and HandlingDispense in a tight container with child-resistant closure.Store at 20°C to 25ºC (68°F to 77ºF); excursions permitted from 15°C to 30ºC (59°F to 86ºF) .The pharmacist should provide an oral dosing device or other suitable measuring device.Storage and HandlingDispense in a tight container with child-resistant closure.Store at 20°C to 25ºC (68°F to 77ºF); excursions permitted from 15°C to 30ºC (59°F to 86ºF) .The pharmacist should provide an oral dosing device or other suitable measuring device.Storage and HandlingDispense in a tight container with child-resistant closure.Store at 20°C to 25ºC (68°F to 77ºF); excursions permitted from 15°C to 30ºC (59°F to 86ºF) .The pharmacist should provide an oral dosing device or other suitable measuring device.Storage and HandlingDispense in a tight container with child-resistant closure.Store at 20°C to 25ºC (68°F to 77ºF); excursions permitted from 15°C to 30ºC (59°F to 86ºF) .The pharmacist should provide an oral dosing device or other suitable measuring device.Dexamethason sodium phosphate injection, USP 10 mg/mL is for-intravenous, intramuscular, intra-articular, intralesional and soft tissue administration available as follows:Dexamethasone sodium phosphate injection, USP mg/mL is for intravenous and intramuscular injection only available as follows:Store at 20ͦ to 25ͦC (68ͦ to 77ͦF). [See USP Controlled Room Temperature.]Protect from light.Sensitive to heat. Do not autoclave. Protect from freezing.Dexamethason sodium phosphate injection, USP 10 mg/mL is for-intravenous, intramuscular, intra-articular, intralesional and soft tissue administration available as follows:Dexamethasone sodium phosphate injection, USP mg/mL is for intravenous and intramuscular injection only available as follows:Store at 20ͦ to 25ͦC (68ͦ to 77ͦF). [See USP Controlled Room Temperature.]Protect from light.Sensitive to heat. Do not autoclave. Protect from freezing.Dexamethason sodium phosphate injection, USP 10 mg/mL is for-intravenous, intramuscular, intra-articular, intralesional and soft tissue administration available as follows:Dexamethasone sodium phosphate injection, USP mg/mL is for intravenous and intramuscular injection only available as follows:Store at 20ͦ to 25ͦC (68ͦ to 77ͦF). [See USP Controlled Room Temperature.]Protect from light.Sensitive to heat. Do not autoclave. Protect from freezing.Dexamethason sodium phosphate injection, USP 10 mg/mL is for-intravenous, intramuscular, intra-articular, intralesional and soft tissue administration available as follows:Dexamethasone sodium phosphate injection, USP mg/mL is for intravenous and intramuscular injection only available as follows:Store at 20ͦ to 25ͦC (68ͦ to 77ͦF). [See USP Controlled Room Temperature.]Protect from light.Sensitive to heat. Do not autoclave. Protect from freezing.Dexamethason sodium phosphate injection, USP 10 mg/mL is for-intravenous, intramuscular, intra-articular, intralesional and soft tissue administration available as follows:Dexamethasone sodium phosphate injection, USP mg/mL is for intravenous and intramuscular injection only available as follows:Store at 20ͦ to 25ͦC (68ͦ to 77ͦF). [See USP Controlled Room Temperature.]Protect from light.Sensitive to heat. Do not autoclave. Protect from freezing.Dexamethason sodium phosphate injection, USP 10 mg/mL is for-intravenous, intramuscular, intra-articular, intralesional and soft tissue administration available as follows:Dexamethasone sodium phosphate injection, USP mg/mL is for intravenous and intramuscular injection only available as follows:Store at 20ͦ to 25ͦC (68ͦ to 77ͦF). [See USP Controlled Room Temperature.]Protect from light.Sensitive to heat. Do not autoclave. Protect from freezing.Dexamethason sodium phosphate injection, USP 10 mg/mL is for-intravenous, intramuscular, intra-articular, intralesional and soft tissue administration available as follows:Dexamethasone sodium phosphate injection, USP mg/mL is for intravenous and intramuscular injection only available as follows:Store at 20ͦ to 25ͦC (68ͦ to 77ͦF). [See USP Controlled Room Temperature.]Protect from light.Sensitive to heat. Do not autoclave. Protect from freezing.Dexamethason sodium phosphate injection, USP 10 mg/mL is for-intravenous, intramuscular, intra-articular, intralesional and soft tissue administration available as follows:Dexamethasone sodium phosphate injection, USP mg/mL is for intravenous and intramuscular injection only available as follows:Store at 20ͦ to 25ͦC (68ͦ to 77ͦF). [See USP Controlled Room Temperature.]Protect from light.Sensitive to heat. Do not autoclave. Protect from freezing.


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.

Non-Clinical Toxicology
ADZENYS ER is contraindicated:

CNS stimulants, including ADZENYS ER, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy

,

]

Drug Interactions:

When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. Profound hypotensive episodes may occur when diazoxide injection and hydralazine injection are used concomitantly.

CNS stimulants, including ADZENYS ER, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy .

The following adverse reactions are discussed in greater detail in other sections of the labeling:

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).